Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1430-1436

  Kogita, Akihiro ^a   Togashi, Yosuke ^a   Hayashi, Hidetoshi ^a   Sogabe, Shunsuke ^a   Terashima, Masato ^a   De Velasco, Marco A ^a   Sakai, Kazuko ^a   Fujita, Yoshihiko ^a   Tomida, Shuta ^a   Takeyama, Yoshifumi ^a   Okuno, Kiyotaka ^a   Nakagawa, Kazuhiko ^a   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ALK inhibitor; EML4 ALK rearrangement; Epithelial mesenchymal transition; Hypoxia; Non small cell lung cancer

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CASPASE 3; CRIZOTINIB; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TRANSCRIPTION FACTOR SLUG; UVOMORULIN; VIMENTIN; CELL CYCLE PROTEIN; EML4 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SERINE PROTEINASE;

APOPTOSIS; ARTICLE; CELL COUNT; CELL ELONGATION; CELL HYPOXIA; CELL MIGRATION; CELL SHAPE; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE REARRANGEMENT; GENE SILENCING; IC 50; IN VITRO STUDY; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; MTT ASSAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPINDLE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84907462932     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2574     Document Type: Article

References (35)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Siegel R, DeSantis C, Virgo K, et al : Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
3. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64, 2002.
4. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
6. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004. (Pubitemid 39209661)
7. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
8. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007. (Pubitemid 47206930)
9. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-170, 2010.
10. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.
11. Seto T, Kiura K, Nishio M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14: 590-598, 2013.
12. Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004. (Pubitemid 38745529)
13. Minakata K, Takahashi F, Nara T, et al: Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 103: 1946-1954, 2012.
14. Murakami A, Takahashi F, Nurwidya F, et al: Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One 9: e86459, 2014.
15. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N and Nishio K: Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64: 9101-9104, 2004. (Pubitemid 39665524)
16. Tanaka K, Arao T, Maegawa M, et al: SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. Int J Cancer 124: 1072-1080, 2009.
17. Kaneda H, Arao T, Tanaka K, et al: FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 70: 2053-2063, 2010.
18. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
19. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.
20. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y and Johnson KR: Cadherin switching. J Cell Sci 121: 727-735, 2008. (Pubitemid 351578108)
21. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
22. Jiang J, Tang YL and Liang XH: EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11: 714-723, 2011.
23. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739, 2010.
24. Katayama R, Shaw AT, Khan TM, et al: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120ra17, 2012.
25. Katayama R, Khan TM, Benes C, et al: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 108: 7535-7540, 2011.
26. Tanizaki J, Okamoto I, Okabe T, et al: Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 18: 6219-6226, 2012.
27. Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK and Lee JC: Epithelial- mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 7: 1093-1102, 2013.
28. Sakamoto H, Tsukaguchi T, Hiroshima S, et al: CH5424802, a selective ALK inhibitor capable of blocking the resistant gate-keeper mutant. Cancer Cell 19: 679-690, 2011.
29. Friboulet L, Li N, Katayama R, et al: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4: 662-673, 2014.
30. Chiou SH, Wang ML, Chou YT, et al: Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70: 10433-10444, 2010.
31. Scheel C and Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22: 396-403, 2012.
32. Rho JK, Choi YJ, Lee JK, et al: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.
33. Suda K, Tomizawa K, Fujii M, et al: Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-1161, 2011.
34. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26, 2011.
35. Kobayashi Y, Sakao Y, Ito S, et al: Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol 8: e75-e78, 2013.